CN Mobile Logo

Search form


ASCO 2016 Lung Cancer

Lung Cancer ASCO Highlights

Cancer Network presents exclusive coverage on lung cancer from the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, with reports, videos, and interviews on the latest clinical research changing the way lung cancer patients are being managed and treated.

ASCO 2016 Lung Cancer

The TKI brigatinib offered good response rates in a phase II trial of patients with ALK-positive non–small-cell lung cancer whose disease progressed on crizotinib.

A Web-based application allows for earlier detection of relapse among patients with advanced lung cancer, improving survival by 7 months.

Post-treatment CT surveillance does not offer better survival rates vs clinical symptoms evaluation for tumor recurrence in locally advanced non–small-cell lung cancer.

Testing for T790M mutations with plasma and urine assays can complement testing done from biopsy tissue in patients with EGFR TKI-resistant NSCLC.

Elderly patients with stage III non–small-cell lung cancer experience poorer overall survival than patients younger than age 70 years when treated with standard concurrent chemoradiotherapy, according to a pooled analysis.

A targeted-sequencing gene panel that includes EGFR, KRAS, PIK3CA, and other mutations from circulating tumor DNA detects stage I non–small-cell lung cancer and might outperform existing tumor markers.

An antibody-drug conjugate, rovalpituzumab tesirine, shows promising efficacy against recurrent small-cell lung cancer.


Subscribe to ASCO 2016 Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.